{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:57:43Z","timestamp":1777777063083,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004083","name":"Ministry of Science ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF- 2020M3A9B6038845"],"award-info":[{"award-number":["NRF- 2020M3A9B6038845"]}],"id":[{"id":"10.13039\/501100004083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.leukres.2021.106754","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T11:34:53Z","timestamp":1637580893000},"page":"106754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2094-6667","authenticated-orcid":false,"given":"Kyung-Mi","family":"Kee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seon-Young","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-U","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon-Won","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Jung","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se-Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4856-7287","authenticated-orcid":false,"given":"Sung-Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3967-4267","authenticated-orcid":false,"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.leukres.2021.106754_bib0005","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2021.106754_bib0010","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.leukres.2021.106754_bib0015","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.leukres.2021.106754_bib0020","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-Year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2021.106754_bib0025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bjh.16381","article-title":"Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)","volume":"189","author":"Do","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.leukres.2021.106754_bib0030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2021.106754_bib0035","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2021.106754_bib0040","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2021.106754_bib0045","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2021.106754_bib0050","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and &10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2021.106754_bib0055","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.2020005514","article-title":"Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia","volume":"137","author":"Shanmuganathan","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2021.106754_bib0060","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1002\/cam4.1753","article-title":"BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors","volume":"7","author":"Song","year":"2018","journal-title":"Cancer Med."},{"issue":"6","key":"10.1016\/j.leukres.2021.106754_bib0065","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2021.106754_bib0070","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.5858\/arpa.2013-0584-OA","article-title":"Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study","volume":"138","author":"Akard","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"4","key":"10.1016\/j.leukres.2021.106754_bib0075","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2404139","article-title":"Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL","volume":"20","author":"Ross","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2021.106754_bib0080","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1046\/j.1365-2141.2002.03705.x","article-title":"Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia","volume":"118","author":"Wang","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2021.106754_bib0085","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00432-014-1746-8","article-title":"Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase","volume":"140","author":"Lauseker","year":"2014","journal-title":"J Cancer Res Clin"},{"issue":"1","key":"10.1016\/j.leukres.2021.106754_bib0090","first-page":"160","article-title":"Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia","volume":"9","author":"Kantarjian","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.leukres.2021.106754_bib0095","first-page":"49","article-title":"Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy","volume":"89","author":"Lange","year":"2004","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2021.106754_bib0100","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"Recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2021.106754_bib0105","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.leukres.2015.01.011","article-title":"Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia","volume":"39","author":"Lee","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2021.106754_bib0110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.leukres.2018.06.002","article-title":"Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib","volume":"70","author":"Lee","year":"2018","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.leukres.2021.106754_bib0115","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2021.106754_bib0120","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-17-0957","article-title":"Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia","volume":"23","author":"Kwak","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.leukres.2021.106754_bib0125","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/blood.V92.11.4059","article-title":"Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha","volume":"92","author":"Mahon","year":"1998","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2021.106754_bib0130","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.leukres.2021.106754_bib0135","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group","volume":"337","author":"Guilhot","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2021.106754_bib0140","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.leu.2402680","article-title":"Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha","volume":"16","author":"Merx","year":"2002","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2021.106754_bib0145","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia","volume":"120","author":"Wang","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2021.106754_bib0150","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1080\/10428194.2016.1239260","article-title":"Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib","volume":"58","author":"Qin","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.leukres.2021.106754_bib0155","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.3390\/ijms20092226","article-title":"Clinical implications of discordant early molecular responses in CML patients treated with imatinib","volume":"20","author":"Stella","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.leukres.2021.106754_bib0160","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.leukres.2021.106754_bib0165","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621017550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621017550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:43:47Z","timestamp":1777488227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621017550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":33,"alternative-id":["S0145212621017550"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106754","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106754"}}